Abbott India Limited (NSE:ABBOTINDIA)

Market Cap	556.07B -9.1%
Revenue (ttm)	71.98B +7.2%
Net Income	16.53B +9.5%
EPS	777.84 +9.5%
Shares Out	n/a
PE Ratio	33.68
Forward PE	30.54
Dividend	656.00 (2.50%)
Ex-Dividend Date	Jul 24, 2026

Volume	5,314
Open	26,780
Previous Close	26,680
Day's Range	26,175 - 26,780
52-Week Range	24,650 - 30,655
Beta	0.08
Analysts	Buy
Price Target	31,907.56 (+21.79%)
Earnings Date	Nov 5, 2026

About Abbott India

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women’s health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1910
• Employees: 3,679
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ABBOTINDIA

Financial Performance

In fiscal year 2026, Abbott India's revenue was 69.29 billion, an increase of 8.11% compared to the previous year's 64.09 billion. Earnings were 15.52 billion, an increase of 9.73%.

Analyst Summary

According to 9 analysts, the average rating for ABBOTINDIA stock is "Buy." The 12-month stock price target is ₹31,908, which is an increase of 21.79% from the latest price.

Price Target

₹31,908

(21.79% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error